Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA)

Walter, Dirk H; Krankenberg, Hans; Balzer, Jörn O; Kalka, Christoph; Baumgartner, Iris; Schlüter, Michael; Tonn, Torsten; Seeger, Florian; Dimmeler, Stefanie; Lindhoff-Last, Edelgard; Zeiher, Andreas M (2011). Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). Circulation: Cardiovascular interventions, 4(1), pp. 26-37. Philadelphia, Pa.: Lippincott Williams & Wilkins 10.1161/CIRCINTERVENTIONS.110.958348

Full text not available from this repository. (Request a copy)

Critical limb ischemia due to peripheral arterial occlusive disease is associated with a severely increased morbidity and mortality. There is no effective pharmacological therapy available. Injection of autologous bone marrow-derived mononuclear cells (BM-MNC) is a promising therapeutic option in patients with critical limb ischemia, but double-blind, randomized trials are lacking.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Angiology

UniBE Contributor:

Baumgartner, Iris

ISSN:

1941-7632

Publisher:

Lippincott Williams & Wilkins

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:11

Last Modified:

16 Jun 2016 10:12

Publisher DOI:

10.1161/CIRCINTERVENTIONS.110.958348

PubMed ID:

21205939

Web of Science ID:

000287351700007

URI:

https://boris.unibe.ch/id/eprint/2224 (FactScience: 204522)

Actions (login required)

Edit item Edit item
Provide Feedback